glp-1 receptor agonists and sglt2 inhibitors Illustration of potential synergistic effects of inhibitor with Complementary Yet Distinct Roles of
Description
Secondary outcomes were each of these events considered separately
Further studies are needed to assess the potential cardiovascular and renal benefits of combination therapy and to determine suitable patient population for the therapy
The GLP-1 drugs market size is predicted to grow from USD 58.05 billion in 2026 to USD 132.79 billion by 2035, driven by a CAGR of 9.63%.
these signals are hypothesis-generating only and do not establish causality or incidence
What is the association between periconceptional GLP-1 receptor agonist exposure and risk of obstetric complications
